Pliant Therapeutics Stock Analysis

PLRX Stock  USD 1.43  0.01  0.70%   
Pliant Therapeutics is undervalued with Real Value of 3.53 and Target Price of 10.06. The main objective of Pliant Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Pliant Therapeutics is worth, separate from its market price. There are two main types of Pliant Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Pliant Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Pliant Therapeutics is usually not traded on Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day. Pliant Stock trading window is adjusted to America/New York timezone.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pliant Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Pliant Stock please use our How to Invest in Pliant Therapeutics guide.

Pliant Stock Analysis Notes

About 97.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.35. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Pliant Therapeutics recorded a loss per share of 3.61. The entity had not issued any dividends in recent years. Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. Pliant Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 110 people. To find out more about Pliant Therapeutics contact MBA MD at 650 481 6770 or learn more at https://pliantrx.com.

Pliant Therapeutics Investment Alerts

Pliant Therapeutics may become a speculative penny stock
Pliant Therapeutics had very high historical volatility over the last 90 days
Pliant Therapeutics has a very high chance of going through financial distress in the upcoming years
Net Loss for the year was (210.3 M) with profit before overhead, payroll, taxes, and interest of 0.
Pliant Therapeutics currently holds about 163.6 M in cash with (155.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.36, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Pliant Therapeutics has a frail financial position based on the latest SEC disclosures
Over 97.0% of the company shares are owned by institutional investors
Latest headline from news.google.com: What drives Pliant Therapeutics Inc. stock price - Explosive trading opportunities - Jammu Links News

Pliant Therapeutics Upcoming and Recent Events

Earnings reports are used by Pliant Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
14th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Pliant Largest EPS Surprises

Earnings surprises can significantly impact Pliant Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2022-02-28
2021-12-31-0.76-0.680.0810 
2022-11-08
2022-09-30-0.74-0.650.0912 
2024-02-27
2023-12-31-0.81-0.690.1214 
View All Earnings Estimates

Pliant Stock Institutional Investors

Shares
Madison Avenue Partners, Lp2025-03-31
1.7 M
Geode Capital Management, Llc2025-03-31
1.4 M
State Street Corp2025-03-31
1.3 M
Acadian Asset Management Llc2025-03-31
1.2 M
Bank Of America Corp2025-03-31
920.7 K
Great Point Partners Llc2025-03-31
850 K
Peapod Lane Capital Llc2025-03-31
642.2 K
Rock Springs Capital Management Lp2025-03-31
590 K
Bessemer Group Inc2025-03-31
532.1 K
Tang Capital Management Llc2025-03-31
M
Deep Track Capital, Lp2025-03-31
5.4 M
Note, although Pliant Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Pliant Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 87.78 M.

Pliant Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.53)(0.56)
Return On Capital Employed(0.63)(0.66)
Return On Assets(0.53)(0.56)
Return On Equity(0.69)(0.66)

Management Efficiency

Pliant Therapeutics has return on total asset (ROA) of (0.3389) % which means that it has lost $0.3389 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6322) %, meaning that it created substantial loss on money invested by shareholders. Pliant Therapeutics' management efficiency ratios could be used to measure how well Pliant Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.56 in 2025. Return On Capital Employed is likely to drop to -0.66 in 2025. At this time, Pliant Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 36.4 M in 2025, whereas Total Assets are likely to drop slightly above 270.7 M in 2025.
Last ReportedProjected for Next Year
Book Value Per Share 5.02  3.82 
Tangible Book Value Per Share 5.02  3.82 
Enterprise Value Over EBITDA(3.44)(3.62)
Price Book Value Ratio 2.62  2.75 
Enterprise Value Multiple(3.44)(3.62)
Price Fair Value 2.62  2.75 
Enterprise Value786.3 M476.5 M
The strategic initiatives led by Pliant Therapeutics' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta
1.356
Return On Assets
(0.34)
Return On Equity
(0.63)

Technical Drivers

As of the 19th of July, Pliant Therapeutics holds the Coefficient Of Variation of 4208.47, risk adjusted performance of 0.0301, and Semi Deviation of 4.37. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pliant Therapeutics, as well as the relationship between them.

Pliant Therapeutics Price Movement Analysis

The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Simple Moving Average indicator is calculated by adding the closing price of Pliant Therapeutics for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Pliant Therapeutics short-term fluctuations and highlight longer-term trends or cycles.

Pliant Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pliant Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pliant Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pliant Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Cline Darren S over a month ago
Acquisition by Cline Darren S of 30000 shares of Pliant Therapeutics at 1.61 subject to Rule 16b-3
 
Crowell Gayle A over a month ago
Acquisition by Crowell Gayle A of 30000 shares of Pliant Therapeutics at 1.61 subject to Rule 16b-3
 
Crowell Gayle A over a month ago
Acquisition by Crowell Gayle A of 30000 shares of Pliant Therapeutics at 1.61 subject to Rule 16b-3
 
Hull Hans over a month ago
Acquisition by Hull Hans of 8791 shares of Pliant Therapeutics at 2.08 subject to Rule 16b-3
 
Coulie Bernard over three months ago
Acquisition by Coulie Bernard of 325000 shares of Pliant Therapeutics at 11.14 subject to Rule 16b-3
 
Lefebvre Eric over three months ago
Acquisition by Lefebvre Eric of 45650 shares of Pliant Therapeutics subject to Rule 16b-3
 
Lefebvre Eric over three months ago
Acquisition by Lefebvre Eric of 91300 shares of Pliant Therapeutics at 11.14 subject to Rule 16b-3
 
Coulie Bernard over three months ago
Acquisition by Coulie Bernard of 325000 shares of Pliant Therapeutics at 11.14 subject to Rule 16b-3
 
Mike Ouimette over three months ago
Disposition of 10230 shares by Mike Ouimette of Pliant Therapeutics at 10.9934 subject to Rule 16b-3
 
Hull Hans over six months ago
Acquisition by Hull Hans of 19337 shares of Pliant Therapeutics subject to Rule 16b-3
 
Pyott David E I over six months ago
Acquisition by Pyott David E I of 26764 shares of Pliant Therapeutics at 13.06 subject to Rule 16b-3
 
Knobil Katharine over six months ago
Acquisition by Knobil Katharine of 26764 shares of Pliant Therapeutics at 13.06 subject to Rule 16b-3

Pliant Therapeutics Outstanding Bonds

Pliant Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Pliant Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Pliant bonds can be classified according to their maturity, which is the date when Pliant Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Pliant Therapeutics Predictive Daily Indicators

Pliant Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Pliant Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Pliant Therapeutics Forecast Models

Pliant Therapeutics' time-series forecasting models are one of many Pliant Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Pliant Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Pliant Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Pliant Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Pliant shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Pliant Therapeutics. By using and applying Pliant Stock analysis, traders can create a robust methodology for identifying Pliant entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(117.43)(111.56)
Operating Profit Margin(134.03)(127.33)
Net Loss(117.43)(111.56)
Gross Profit Margin 0.56  0.48 

Current Pliant Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Pliant analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Pliant analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
10.06Buy13Odds
Pliant Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Pliant analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Pliant stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Pliant Therapeutics, talking to its executives and customers, or listening to Pliant conference calls.
Pliant Analyst Advice Details

Pliant Stock Analysis Indicators

Pliant Therapeutics stock analysis indicators help investors evaluate how Pliant Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Pliant Therapeutics shares will generate the highest return on investment. By understating and applying Pliant Therapeutics stock analysis, traders can identify Pliant Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow64.7 M
Long Term Debt30.2 M
Common Stock Shares Outstanding60.5 M
Total Stockholder Equity304.1 M
Total Cashflows From Investing Activities140.3 M
Property Plant And Equipment Net32.8 M
Cash And Short Term Investments355.7 M
Cash71.2 M
Accounts PayableM
Net Debt-11 M
50 Day M A1.3756
Total Current Liabilities33.2 M
Non Current Assets Total34.7 M
Non Currrent Assets Other1.9 M
Stock Based Compensation37.6 M

Additional Tools for Pliant Stock Analysis

When running Pliant Therapeutics' price analysis, check to measure Pliant Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant Therapeutics is operating at the current time. Most of Pliant Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pliant Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant Therapeutics' price. Additionally, you may evaluate how the addition of Pliant Therapeutics to your portfolios can decrease your overall portfolio volatility.